Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$13.64
+0.1%
$12.47
$8.04
$25.88
$373.73M2.27421,186 shs172,653 shs
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$1.91
+4.3%
$1.82
$1.33
$2.89
$55.59M1.75412,266 shs180,983 shs
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$22.09
+0.8%
$20.34
$13.45
$44.42
$1.94B0.031.03 million shs522,894 shs
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
$35.87
+2.0%
$35.99
$1.72
$54.30
$221.68M1.01362,174 shs24,007 shs
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$0.34
+4.1%
$0.31
$0.24
$1.47
$24.06M0.13434,742 shs283,192 shs
Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.00%+2.29%+14.48%+49.67%-37.82%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
0.00%+4.89%+1.54%+25.59%+8.47%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
0.00%+3.37%+4.69%+50.17%-33.64%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
0.00%+6.76%-5.63%+19.57%+919.90%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.00%+13.91%+9.80%+22.16%-54.24%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.7667 of 5 stars
4.62.00.00.03.22.50.6
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
2.149 of 5 stars
3.51.00.00.00.63.30.6
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
3.4697 of 5 stars
3.51.00.04.40.91.70.0
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
3.0401 of 5 stars
3.45.00.00.02.71.70.0
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
4.3758 of 5 stars
3.63.00.04.61.62.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
3.11
Buy$54.00296.04% Upside
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
3.00
Buy$21.001,000.05% Upside
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
2.93
Moderate Buy$53.42141.81% Upside
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
2.80
Moderate Buy$56.5057.51% Upside
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
3.20
Buy$3.13808.43% Upside

Current Analyst Ratings Breakdown

Latest OVID, IDYA, FBIO, MNPR, and ARCT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/2/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform
7/2/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetSector Outperform ➝ Sector Outperform$32.00 ➝ $35.00
6/26/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$44.00
6/26/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$44.00
6/23/2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$60.00
5/28/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$32.00
5/27/2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$2.00 ➝ $1.50
5/22/2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$63.00 ➝ $66.00
5/14/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$50.00 ➝ $45.00
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/13/2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$68.00 ➝ $66.00
(Data available from 7/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
$152.31M2.43N/AN/A$8.90 per share1.53
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
$57.67M0.98N/AN/A($0.06) per share-31.82
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
$7M276.38N/AN/A$12.25 per share1.80
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/A$9.02 per shareN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
$548K44.64N/AN/A$0.96 per share0.36
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$80.94M-$2.53N/AN/AN/A-47.47%-27.41%-19.01%8/4/2025 (Estimated)
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
-$46M-$2.23N/AN/AN/A-71.24%-4,712.53%-27.67%8/12/2025 (Estimated)
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$274.48M-$3.59N/AN/AN/AN/A-29.28%-27.68%8/5/2025 (Estimated)
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$15.59M-$3.48N/AN/AN/AN/A-55.39%-51.53%8/8/2025 (Estimated)
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$26.43M-$0.35N/AN/AN/A-4,562.23%-34.17%-25.34%8/12/2025 (Estimated)

Latest OVID, IDYA, FBIO, MNPR, and ARCT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/13/2025Q1 2025
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
-$0.65-$0.38+$0.27-$0.38N/AN/A
5/13/2025Q1 2025
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
-$0.14-$0.14N/A-$0.14$0.03 million$0.13 million
5/12/2025Q1 2025
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
-$1.58-$0.52+$1.06-$0.52$25.64 million$29.38 million
5/6/2025Q1 2025
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
-$0.75-$0.82-$0.07-$0.82$2.10 millionN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
N/AN/AN/AN/AN/A
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
N/AN/AN/AN/AN/A
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/AN/AN/AN/AN/A
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/AN/AN/AN/AN/A
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
0.06
5.64
5.64
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
1.74
1.72
1.55
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
N/A
13.92
13.92
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
N/A
36.91
36.91
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
0.22
4.93
4.93

Institutional Ownership

CompanyInstitutional Ownership
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
94.54%
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
96.51%
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
98.29%
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
1.83%
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
72.24%
CompanyEmployeesShares OutstandingFree FloatOptionable
Arcturus Therapeutics Holdings Inc. stock logo
ARCT
Arcturus Therapeutics
18027.12 million22.62 millionOptionable
Fortress Biotech, Inc. stock logo
FBIO
Fortress Biotech
17029.57 million21.32 millionOptionable
IDEAYA Biosciences, Inc. stock logo
IDYA
IDEAYA Biosciences
8087.58 million85.39 millionOptionable
Monopar Therapeutics Inc. stock logo
MNPR
Monopar Therapeutics
106.12 million4.86 millionNot Optionable
Ovid Therapeutics stock logo
OVID
Ovid Therapeutics
6071.11 million61.80 millionOptionable

Recent News About These Companies

Ovid Therapeutics Inc Chart - Morningstar
Juneberry Farm in Ovid opens for u-pick season
Ovid man, 81, charged with DWI after near-crash
Ovid Therapeutics (OVID) Receives a Buy from TD Cowen

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Arcturus Therapeutics stock logo

Arcturus Therapeutics NASDAQ:ARCT

$13.64 +0.02 (+0.11%)
As of 07/3/2025 03:11 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Fortress Biotech stock logo

Fortress Biotech NASDAQ:FBIO

$1.91 +0.08 (+4.32%)
As of 07/3/2025 03:36 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Fortress Biotech, Inc., a biopharmaceutical company, develops dermatology, pharmaceutical, and biotechnology products in the United States. The company markets dermatology products, such as Qbrexza a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane capsules for severe recalcitrant nodular acne; Amzeeq for severe acne vulgaris; Zilxi, a topical foam; Exelderm cream and solution for topical use; Targadox an oral doxycycline drug for adjunctive therapy for severe acne; Luxamend; sulconazole nitrate cream and solution for tinea cruris and tinea corporis; and doxycycline hyclate tablet. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; Cosibelimab for metastatic cancers; Olafertinib for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and DFD-29 for the treatment of rosacea. The company's early stage product candidates include Dotinurad for gout; MB-106 for B-cell non-hodgkin lymphoma; MB-101 for glioblastoma; MB-108 for recurrent GBM; MB-109 for refractory glioblastoma; AJ201, an androgen receptor degradation enhancer; BAER-101, a positive allosteric modulator; MB-117 for newly diagnosed x-linked severe combined immunodeficiency; and MB217 for previously transplanted; and MB-110 for RAG1 severe combined immunodeficiency. Its preclinical product candidates comprise Mayo Clinic In Vivo CAR T Platform Technology; AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; and oligonucleotide platform. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Islands, Florida.

IDEAYA Biosciences stock logo

IDEAYA Biosciences NASDAQ:IDYA

$22.09 +0.17 (+0.78%)
As of 07/3/2025 01:04 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Monopar Therapeutics stock logo

Monopar Therapeutics NASDAQ:MNPR

$35.87 +0.71 (+2.02%)
Closing price 07/3/2025 01:04 PM Eastern
Extended Trading
$35.87 0.00 (0.00%)
As of 07/3/2025 04:23 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

Ovid Therapeutics stock logo

Ovid Therapeutics NASDAQ:OVID

$0.34 +0.01 (+4.08%)
Closing price 07/3/2025 03:58 PM Eastern
Extended Trading
$0.35 +0.01 (+2.91%)
As of 07/3/2025 04:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.